2026-03-12 - ISRG - Intuitive Surgical Deep Dive

Deep Dive Ticker Tape
1 min read

2026-03-12 - ISRG - Intuitive Surgical Deep Dive

1 tickers referenced · published Mar 12, 2026

Article published Mar 12, 2026. Prices below use latest available snapshots.

ISRG $390.33 +13.0% 30d

Conviction: Medium-High Status: Accumulate — RSI 35.2, price $478.70, below SMA, approaching oversold

Quick Snapshot

Signal Reading
Overall 🟡 RSI 35.2 — approaching oversold. Price $478.70, -2.9% today, -3.6% 7D, flat 30D. SMA20 ~$494.88 — price -3.3% below SMA.
Moat Wide (surgical robotics monopoly — da Vinci system)
Key insight ISRG continues to slide from $485.85 (03/11) to $478.70 (-1.5%). RSI declined from 39.6 to 35.2 — approaching oversold again. Price is further below SMA. The da Vinci monopoly thesis is unquestionably intact. At RSI 35 in the entry zone with a monopoly moat, this is an accumulate.

Action Matrix

Action Level Why
Current 📈 Accumulate RSI 35.2 approaching oversold, in entry zone, monopoly moat.
Entry Zone $470 - $500 Current $478.70 — IN ZONE
Stop-Loss $405 (-15%) Below key support
Target $600 (+25%) Recovery toward recent levels

Price Data

Stock Price 1D 7D 30D 3M RSI Status Action
ISRG $478.70 -2.9% -3.6% 0.0% -11.7% 35 🟡 Approaching Oversold 📈 Accumulate

Price vs Last Deep Dive (03/11)

Metric 03/11 03/12 Change
Price $485.85 $478.70 -$7.15 (-1.5%)
RSI 39.6 35.2 -4.4 (declining)
SMA20 ~$495.86 ~$494.88 -$0.98
vs SMA -2.0% -3.3% Further below SMA

Update from 03/11: Continued slide. RSI declining toward oversold at 35.2. Price further below SMA at -3.3%. The da Vinci monopoly + consumable flywheel thesis completely intact. Approaching the ideal accumulate zone. At RSI 35 below SMA with the widest moat in medtech, this is actionable.

Company Overview

One-Liner

Intuitive Surgical manufactures the da Vinci robotic surgical system, with a near-monopoly in soft-tissue robotic surgery.

Competitive Moat

Moat Type Present? Evidence
Switching costs 🟢 Surgeon training 12-18 months, $2M+ investment
Intangible assets 🟢 10,000+ patents, FDA approvals, 30+ years data
Network effects 🟢 More procedures = more outcome data = more placements
Efficient scale 🟢 10,000+ installed systems globally

Moat Width: Wide Moat Trend: Widening — da Vinci 5 driving upgrade cycle

Bull Case

  1. da Vinci monopoly — 10,000+ installed systems. No serious competitor for 5+ years.
  2. Recurring consumable flywheel — Each system generates $500K-$1M+ annually.
  3. RSI 8.8 → 35: recovery + approaching oversold again — Second entry opportunity forming.
  4. da Vinci 5 upgrade cycle — New generation driving replacements.

Bear Case

  1. Insider selling persists — $282.6M net selling.
  2. -2.9% today, -3.6% 7D — Active selling pressure.
  3. Medtronic Hugo FDA approval risk — Long-term competitive threat.

Research Log

Date Update
2026-02-16 Created. RSI 8.8 extreme. $476.32. Action: Buy.
2026-02-22 Data stale.
2026-03-03 Data stale. 4 weeks.
2026-03-11 FRESH DATA. $485.85. RSI 39.6. RSI recovered from 8.8 extreme. Accumulate.
2026-03-12 Continued slide. $478.70 (-1.5%). RSI 35.2. Approaching oversold. Accumulate.

The Gold

Key Discoveries

Discovery Implication
RSI 8.8 → 39.6 → 35.2 Recovery stalled, now approaching oversold again
Price declined while SMA declined with it Structural weakness, not just a short-term noise
30D flat despite all the volatility Range-bound — waiting for catalyst

Open Questions

  • What is da Vinci 5 placement pace?
  • Are insider sales on 10b5-1 schedule?
  • What is procedure growth rate in Q1 2026?